Seres Other Cashflows From Financing Activities from 2010 to 2024
| MCRB Stock | USD 0.89 0.12 15.58% |
Other Cashflows From Financing Activities | First Reported 2013-12-31 | Previous Quarter 1.3 M | Current Value -114.3 M | Quarterly Volatility 56.6 M |
Check Seres Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Seres Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 15.9 M, Interest Expense of 13.8 M or Selling General Administrative of 92.1 M, as well as many indicators such as Price To Sales Ratio of 1.35, Dividend Yield of 0.0 or Days Sales Outstanding of 39.22. Seres financial statements analysis is a perfect complement when working with Seres Therapeutics Valuation or Volatility modules.
Seres | Other Cashflows From Financing Activities |
Latest Seres Therapeutics' Other Cashflows From Financing Activities Growth Pattern
Below is the plot of the Other Cashflows From Financing Activities of Seres Therapeutics over the last few years. It is Seres Therapeutics' Other Cashflows From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Seres Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Cashflows From Financing Activities | 10 Years Trend |
|
Other Cashflows From Financing Activities |
| Timeline |
Seres Other Cashflows From Financing Activities Regression Statistics
| Arithmetic Mean | 24,817,907 | |
| Geometric Mean | 5,182,126 | |
| Coefficient Of Variation | 183.23 | |
| Mean Deviation | 32,036,571 | |
| Median | 3,028,000 | |
| Standard Deviation | 45,473,120 | |
| Sample Variance | 2067.8T | |
| Range | 140.2M | |
| R-Value | (0.22) | |
| Mean Square Error | 2119.9T | |
| R-Squared | 0.05 | |
| Significance | 0.43 | |
| Slope | (2,228,203) | |
| Total Sum of Squares | 28949.3T |
Seres Other Cashflows From Financing Activities History
About Seres Therapeutics Financial Statements
Seres Therapeutics stakeholders use historical fundamental indicators, such as Seres Therapeutics' Other Cashflows From Financing Activities, to determine how well the company is positioned to perform in the future. Although Seres Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Seres Therapeutics' assets and liabilities are reflected in the revenues and expenses on Seres Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Seres Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Cashflows From Financing Activities | 3 M | 2.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out the analysis of Seres Therapeutics Correlation against competitors. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.